Skip to main content
African Journal of Traditional, Complementary, and Alternative Medicines logoLink to African Journal of Traditional, Complementary, and Alternative Medicines
. 2016 Jul 3;13(4):42–46. doi: 10.21010/ajtcam.v13i4.7

IN VITRO ANTIMICROBIAL ACTIVITY SCREENING OF XYLARIA HYPOXYLON

Kerem Canli 1,*, Ilgaz Akata 2, Ergin Murat Altuner 3
PMCID: PMC5566152  PMID: 28852719

Abstract

Background:

Fungi have a potential of using both as nutritive and medicinal food stuff. Because of containing several therapeutic agents, they are reported to be used for hundreds of years to treat several diseases caused by bacteria, fungi, viruses and parasites. The aim of this study is to determine the in vitro antimicrobial activity of Xylaria hypoxylon, which were collected from Yomra, Trabzon, Turkey.

Materials and Methods:

X. hypoxylon samples were air dried and extracted by using ethanol. Antimicrobial activity of X. hypoxylon ethanol extracts were investigated against 21 bacterial and 2 fungal strains, namely, Bacillus subtilis DSMZ 1971, Bacillus subtilis ATCC 6633, Candida albicans ATCC 10231, Candida albicans DSMZ 1386, Enterobacter aerogenes ATCC 13048, Enterococcus durans, Enterococcus faecalis ATCC 29212, Enterococcus faecium, Escherichia coli ATCC 25922, Escherichia coli CFAI, Klebsiella pneumoniae, Listeria innocula, Listeria monocytogenes ATCC 7644, Pseudomonas aeruginosa DSMZ 50071, Pseudomonas fluorescence P1, Salmonella enteritidis ATCC 13075, Salmonella infantis, Salmonella kentucky, Salmonella typhimurium SL 1344, Staphylococcus aureus ATCC 25923, Staphylococcus carnosus MC1.B, Staphylococcus epidermidis DSMZ 20044 and Streptococcus agalactiae DSMZ 6784 by using the disk diffusion method.

Results:

It is observed that ethanol extracts of X. hypoxylon has antimicrobial activity against several Gram positive and Gram negative microorganisms tested. As a result of the study, an antimicrobial activity of X. hypoxylon found against most of strains used in the study.

Conclusion:

The results of our study clearly puts forward that X. hypoxylon could have a possible medicinal use.

Keywords: Xylaria hypoxylon, fungi, antimicrobial activity, antimicrobial screening, ethanol extract

Introduction

From the beginning of the history humankind natural products have provided a variety of medicines (Webster et al., 2008). It has been known for many years that natural products have potential of containing therapeutic agents as a source for analgesics, anti-inflammatories, anti-neoplastic drugs, medicines for asthma, anti-arrhythmic agents, anti-hypertensives and anti-infective agents against several infectious diseases (Clardy and Walsh, 2004; Webster et al., 2008; Altuner et al., 2010a, b). Natural products play a central role in the health care of about 80% of the world’s population (Baker et al., 1995).

Microbial evolution and antibiotic resistance as a result of the increase in use of anti-infective drugs worldwide has been defined as the major threat for the public health in the 21st century by World Health Organization (Syed et al., 2010). This dramatic increase is being associated with important morbidity and mortality in immune compromised patients (Kontoyiannis et al., 2003; Kauffman, 2006).

A tremendous progress has been made in human medicine in the last decades, but bacterial, fungal and viral diseases are still threatening the public health in the developing countries (Cos et al., 2006). The major problem in these countries is the extensive drug resistance which has a large impact on human health (Okeke et al., 2005), thus there is a continuous need to discover new antimicrobial compounds having diverse chemical structures and novel mechanisms of action (Rojas et al., 2003; Ertürk et al., 2006).

In order to prevent spreading of infection by antibiotic resistant microbes, scientists have been conducting intensive researches to determine new alternative antimicrobial agents (Paudel et al., 2008; Özkan et al., 2015).

Huge number of studies presented that natural products have been used for hundreds of years to treat several diseases caused by bacteria, fungi, viruses and parasites (Jones, 1996; Onbaşılı et al., 2011; Onbaşlı et al., 2013). Recent researches showed that natural products have a potential of providing opportunities for new drug leads. As far as the current literature is concerned, it is obvious that only a very small amount of the available diversity among living organisms have yet been explored for such purposes (Cos et al., 2006, Altuner, 2011).

After Fleming has discovered penicillin accidentally from Penicillium fungi, scientific attention has widely be attracted for the potential role of fungi as antimicrobial agents, which has lead to the discovery and development of new antimicrobial agents (Bala et al., 2011).

Fungi have a potential of using both as nutritive and medicinal food (Bonatti et al., 2004; Agrahar-Murugkar and Subbulakshmi, 2005; Cheung and Cheung, 2005; Imtiaj and Lee, 2007).

Some species such as Agaricus bisporus (J. E. Lange) Imbach (Agaricaceae) are frequently used as a food source, while some are very toxic such as Amanitas. In addition, some fungi have been used as medicines to prevent diseases such as hypertension, hypercholesterolemia and cancer (Bobek et al., 1995; Bobek and Galbavy, 1999).

Several compounds have been isolated and identified by researchers originating from fungi until now, which show medicinal properties, such as immune modulatory, liver protective, antifibrotic, anti-inflamatory, antidiabetic, antiviral and antimicrobial activities (Dülger et al., 1999; Gunde-Cimerman, 1999; Ooi, 2000;Wasser and Weis, 1999a, b; Dülger et al., 2005b). Xylaria hypoxylon (L.) Grev. belongs to family Xylariaceae Tul. & C. Tul. (Ascomycota). It is very common species, can be collected during the year on dead wood of dedicious trees (Breitenbach and Kränzlin, 1984; Breitenbach and Kränzlin, 1986; Hansen and Knudsen,2000).

In this study the antimicrobial activity of X. hypoxylon is investigated against Bacillus subtilis DSMZ 1971, Bacillus subtilis ATCC 6633, Candida albicans ATCC 10231 , Candida albicans DSMZ 1386, Enterobacter aerogenes ATCC 13048, Enterococcus durans, Enterococcus faecalis ATCC 29212, Enterococcus faecium, Escherichia coli ATCC 25922, Escherichia coli CFAI, Klebsiella pneumoniae, Listeria innocula, Listeria monocytogenes ATCC 7644, Pseudomonas aeruginosa DSMZ 50071 , Pseudomonas fluorescence P1 , Salmonella enteritidis ATCC 13075, Salmonella infantis, Salmonella kentucky, Salmonella typhimurium SL 1344, Staphylococcusaureus ATCC 25923, Staphylococcuscarnosus MC1.B, Staphylococcusepidermidis DSMZ 20044 and Streptococcus agalactiae DSMZ 6784 by using the disk diffusion method.

Materials and Methods

Macrofungi samples

X. hypoxylon samples used in this study were collected from Yomra, Trabzon, which is located in the Black Sea region of Turkey. Voucher specimens were deposited for further reference in Herbarium of Ankara University (ANK) Faculty of Science, Department of Biology, Ankara, Turkey.

Extraction procedure

All X. hypoxylon samples were dried out after collection and the samples were grounded by a mortar and a pestle. In order to extract active substances ethanol (Merck, Germany) was chosen as an extraction solvent. Grounded samples were shaken in ethanol at 100 rpm for 3 days at room temperature. All the extracts were filtered through Whatman No. 1 filter paper into evaporation flasks. The filtrate was evaporated by a rotary evaporator (Heidolph Hei-Va p Value HL/HB-G1) at 30°C. After evaporation the residues were collected and used to prepare 9 mg.mL-1 extracts.

Microorganisms

A wide range of Gram positive and Gram negative bacteria and yeasts were selected to test the antimicrobial effect of X. hypoxylon. These strains are Bacillus subtilis DSMZ 1971, Bacillus subtilis ATCC 6633, Candida albicans ATCC 10231, Candida albicans DSMZ 1386, Enterobacter aerogenes ATCC 13048, Enterococcus durans, Enterococcus faecalis ATCC 29212, Enterococcus faecium, Escherichia coli ATCC 25922, Escherichia coli CFAI, Klebsiella pneumoniae, Listeria innocula, Listeria monocytogenes ATCC 7644, Pseudomonas aeruginosa DSMZ 50071, Pseudomonas fluorescence P1, Salmonella enteritidis ATCC 13075, Salmonella infantis, Salmonella kentucky, Salmonella typhimurium SL 1344, Staphylococcus aureus ATCC 25923, Staphylococcuscarnosus MC1.B, Staphylococcusepidermidis DSMZ 20044 and Streptococcusagalactiae DSMZ 6784. The strains were chosen from standard strains as much as possible. Other strains which are not standard were all isolated from food and identified in Ankara University, Faculty of Science, Department of Biology.

Preparation of inocula

All bacterial strains were incubated at 37 °C for 24 hours (Canlı et al., 2015). But since the requirements for C. albicans is different, C. albicans was inoculated at 27 °C for 48 hours. Inocula were prepared by transferring morphologically similar colonies of each organism into 0.9% sterile saline solution until the visible turbidity was equal to 0.5 McFarland standard having approximately 108 cfu.mL-1 for bacteria and 107 cfu.mL-1 for C. albicans (Hammer et al., 1999; Altuner et al., 2012a, b; Canlı et al., 2014).

Disk diffusion method

Disk diffusion test was performed as described previously by Andrews (Andrews, 2003). The culture medium was poured into 120 mm sterile Petri dish to give a mean depth of 4.0 mm ± 0.5 mm (Altuner and Çetin, 2009; Altuner and Akata, 2010). 60 μL, 100 μL and 150 μL aliquots of each extract was applied on sterile paper disks of 6 mm diameter end up with 550 μg.μL-1, 917 μg.μL-1 and 1375 μg.μL-1 sample on each disk (Mahasneh and El-Oqlah, 1999; Silici and Koc, 2006). To get rid of any residual solvent which might interfere with the results, disks were left to dry overnight at 30°C in sterile conditions (Silici and Koc, 2006; Altuner and Çetin, 2010, Altuner and Canlı, 2012). The surface of the plates was inoculated using previously prepared inocula containing saline suspension of microorganisms. Inoculated plates were then left to dry for 5 minutes at room temperature before applying the disks (Altuner et al., 2014). Disks were firmly applied to the surface of the plate which had an even contact with the agar. Plates were incubated and inhibition zone diameters were expressed in millimetres (Altuneretal., 2011a, b).

Controls

Empty sterile disks and extraction solvent (ethanol) loaded on sterile disks which were dried at sterile conditions to remove solvent as done in the study were used as negative controls.

Statistics

All extracts were tested in triplicate and MACANOVA (version 5.05) was used for statistical analysis of the data. P values of <0.05 were considered statistically significant.

Results and Discussion

In this test, extracts were loaded on empty sterile disks and these disks were then applied on a culture medium inoculated with microorganisms. If the extracts were active against these microorganisms, they have caused an inhibition zone. The diameters of the inhibition zones recorded in millimetres are given in Table 1. No activity was observed for the negative controls; extraction solvent and empty sterile disks.

Table 1.

Disk diffusion test results (Inhibition zones in mm)

30μL 60μL 150μL
B. subtilis ATCC 6633 - 7 11
B. subtilis DSMZ 1386 10 11 13
C. albicans ATCC 10231 7 8 9
C. albicans DSMZ 1386 - - -
E. aerogenes ATCC 13048 7 7 7
E. durans 8 8 9
E.faecalis ATCC 29212 - - 10
E. faecium 9 10 12
E. coli ATCC 25922 7 7 10
E. coli CFAI - - -
K. pneumonia 7 8 8
L. innocula 7 7 9
L. monocytogenes ATCC 7644 10 12 13
P. aeruginosa DSMZ 50071 - - -
P. fluorescens P1 - 7 9
S. enteritidis ATCC 13075 - - -
S. infantis - - -
S. Kentucky 7 7 7
S. typhimurium SL 1344 - - 8
S. aureus ATCC 25923 16 16 16
S. carnosus MC1.B - - 9
S. epidermidis DSMZ 20044 7 8 11
S. agalactiae DSMZ 6784 - - 8

“_“:No activity observed.

Results given in Table 1 show that 30 μL (550 μg.μL-1) of X. hypoxylon samples caused an inhibition zone of 16 mm against S. aureus ATCC 25923, 10 mm against B. subtilis DSMZ 1386 and L. monocytogenes ATCC 7644, 9 mm against E. faecium, 8 mm against E. durans, 7 mm against C. albicans ATCC 10231, E. aerogenes ATCC 13048, E. coli ATCC 25922, K. pneumoniae, L. innocula, S. kentucky and S. epidermidis DSMZ 20044. 60 μL (917 μg.μL-1) of X. hypoxylon samples caused an inhibition zone of 16 mm against S. aureus ATCC 25923, 12 mm against L. monocytogenes ATCC 7644, 11 mm against B. subtilis DSMZ 1386, 10 mm against E. faecium, 8 mm against C. albicans ATCC 10231, E. durans, K. pneumoniae and S. epidermidis DSMZ 20044, 7 mm against B. subtilis ATCC 6633, E. coli ATCC 25922, L. innocula, P. fluorescens P1 and S. kentucky, where 150 μL (1375 μg.μL-1) of X. hypoxylon samples caused an inhibition zone of 16 mm against S. aureus ATCC 25923, 13 mm against B. subtilis DSMZ 1386 and L. monocytogenes ATCC 7644, 12 mm against E. faecium, 11 mm against B. subtilis ATCC 6633 and S. epidermidis DSMZ 20044, 10 mm against E. coli ATCC 25922, 9 mm against C. albicans ATCC 10231, E. durans, L. innocula, P. fluorescens P1 and S. carnosus MC1.B, 8 mm against K. pneumoniae, S. typhimurium SL 1344 and S. agalactiae DSMZ 6784, 7 mm against E. aerogenes ATCC 13048 and S. kentucky.

On the other hand, no inhibition zone was observed against C. albicans DSMZ 1386, E.coli CFAI, P. aeruginosa DSMZ 50071, S. enteritidis ATCC 13075 and S. infantis.

It is a fact that Gram-negative bacteria are more resistant to a large number of chemotherapeutic agents than Gram-positive bacteria (Nikaido, 1998). It was previously reported that antibiotics of natural origin showed >90% lacked activity against E. coli strains, although they were active against Gram-positive strains (Vaara, 1993). Thus, any antimicrobial activity against E. coli can be very important.

As far as the current literature considered there are no results reported regarding the antibacterial activity of any Fungi samples or any plant samples against E. coli CFAI until now. However, there are several studies reported by using other E. coli strains. For example, Dulger et al. (2005a) showed that the methanolic extract of H. cupressiforme (30mg.mL-1) presented 12.2 mm of inhibition zone against E. coli ATCC 11230. When the results reported by Dulger et al. (2005a) were compared with our results, which were maximum 10 mm inhibition zone against E. coli ATCC 25922, it can be concluded that ethanolic extract of X. hypoxylon presented lower antimicrobial activity. But since the E. coli strain used in this study is different than the study conducted by Dulger et al. (2005a), this difference is not comparable.

It was also pointed out previously that Gram-negative bacteria are the dominant killers among bacterial infections in the Intensive Care Units (ICU) (Villegas and Quinn, 2004). Klebsiella is one of the Gram-negative microorganisms that cause death in ICUs (Villegas and Quinn, 2004), so having antibacterial activity against K. pneumoniae may be very important.

Quereshi et al. (2010) identified that 40 μg.mL-1 of Ganoderma lucidum caused 11.30 mm of inhibition zone against K. pneumoniae. In our study we observed 8 mm of inhibition zone with 917 μg.μL-1 of X. hypoxylon extract. By comparing these two studies it can be concluded that ethanolic extracts of X. hypoxylon has lower antimicrobial activity against K. pneumoniae when compared to G. lucidum, but on the other hand 8 mm of inhibition zone can be accepted as a moderate activity when compared to other studies.

The pathogenicity of B. subtilis is described as low or absent (De Boer and Diderichsen, 1991). B. subtilis is only known to cause disease in immunocompromised patients (Galieni and Bigazzi, 1998). Several researchers study antimicrobial activity of some plant extracts on B. subtilis strains. For example, Khalid et al. (2011) compared four different methanolic plant extracts, namely Zingiber officinale, Swertia chirata, Polygonum bistorta and Pistacia integerrim. In this study maximum 30 mg of extracts were loaded on sterile antibiotic disks and inhibition zones were found to be 17 mm for Z. officinale, 12 mm for P. integerrim, 12 mm for S. chirata and 11 mm for P. bistorta. In our study we observed 13 mm zone for 1.375 mg of X. hypoxylon extract which is about 22 times lower than the amount used for study conducted by Khalid et al. (2011). Comparing these results clearly puts forward how X. hypoxylon is active against B. subtilis when compared to some higher plants.

It was reported that although serovar Typhimurium has a less alarming public image than serovar Typhi of Salmonella it is a bigger health problem and it is thought by researchers to be underreported (McClelland et al., 2001). There are probably hundreds of millions of cases every year in the world in which serovar Typhimurium kill twice as many people as serovar Typhi, which were mostly infants and the elderly patients (McClelland et al., 2001). According to results, 150 μL of X. hypoxylon extract showed low antibacterial activity against S. typhimurium SL 1344. Since the inhibition zone is quite low, increasing the active substance loaded on the empty sterile antibiotic disks may also increase the activity.

Conclusion

As a result, it can be concluded that there is clear antimicrobial activity of X. hypoxylon sample against most of the strains tested. The results of our study clearly puts forward that X. hypoxylon could have a possible medicinal uses especially against B. subtilis ATCC 6633, B. subtilis DSMZ 1386, E. faecium, L. monocytogenes ATCC 7644 and S. aureus ATCC 25923. But further researches are needed to be conducted in order to analyse the active substances in details.

Footnotes

Conflict of Interests: The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  • 1.Agrahar-Murugkar D, Subbulakshmi G. Nutritional value of edible wild mushrooms collected from Khasi hills of Meghalaya. Food Chemistry. 2005;89:599–603. [Google Scholar]
  • 2.Altuner E. M. Investigation of antimicrobial activity of Punica granatum L. Fruit peel ash used for protective against skin infections as folk remedies especially after male circumcision. African Journal of Microbiology Research. 2011;5(20):3339–3342. [Google Scholar]
  • 3.Altuner E. M, Akata I. Antimicrobial Activity of Some Macrofungi Extracts. Sakarya Üniversitesi Fen Bilimleri EnstitüsüDergisi. 2010;14:45–49. [Google Scholar]
  • 4.Altuner E. M, Akata I, Canli K. In vitro antimicrobial screening of Bovista nigrescens (Pers.) Kastamonu University, Journal of Forestry. 2012a;12(1):90–96. [Google Scholar]
  • 5.Altuner E. M, Akata I, Canli K. In vitro antimicrobial screening of Cerena unicolor (Bull.) Murrill (Polyporaceae Fr. Ex Corda) Fresenius Environmental Bulletin. 2012b;21(1B):3704–3710. [Google Scholar]
  • 6.Altuner E. M, Canli K. In vitro antimicrobial screening of Hypnum andoi A.J.E. Sm.. Kastamonu University. Journal of Forestry. 2012;12(1):97–101. [Google Scholar]
  • 7.Altuner E. M, Canli K, Akata I. Antimicrobial Screening of Calliergonella cuspidata, Dicranum polysetum and Hypnum cupressiforme. Journal of Pure and Applied Microbiology. 2014;8(1):539–545. [Google Scholar]
  • 8.Altuner E. M, Ceter T, Islek C. Investigation of antifungal activity of Ononis spinosa L. ash used for the therapy of skin infections as folk remedies. Mikrobiyoloji Bulteni. 2010a;44:633–639. [PubMed] [Google Scholar]
  • 9.Altuner E. M, Cetin B. Antimicrobial activity of Thuidium delicatulum (Bryopsida) extracts. Kafkas Universitesi, Fen Bilimleri Enstitusu Dergisi. 2009;2:85–92. [Google Scholar]
  • 10.Altuner E. M, Cetin B. Antimicrobial activity of Tortella tortulosa (Hedw.) Limpr. Extracts. Kastamonu University. Journal of Forestry. 2010;10:111–116. [Google Scholar]
  • 11.Altuner E. M, Cetin B, Cokmus C. Antimicrobial Screening of Some Mosses Collected From Anatolia. Pharmacognosy Magazine. 2010b;6(22):56. [Google Scholar]
  • 12.Altuner E. M, Ceter T, Bayar E, Aydin S, Arici F, Suleymanoglu G, Edis A. Investigation on Antimicrobial Effects of Some Moss Species Collected From Kastamonu Region. Communications Faculty of Sciences University of Ankara Series C: Biology. 2011a;23(1-2):33–43. [Google Scholar]
  • 13.Altuner E.M, Ceter T, Demirkapi D, Ozkay K, Hayal U, Eser G. Investigation on Antimicrobial Effects of Some Lichen Species Collected From Kastamonu Region. Communications Faculty of Sciences University of Ankara Series C: Biology. 2011b;23(1-2):21–31. [Google Scholar]
  • 14.Andrews J. M. BSAC standardized disc susceptibility testing method (version 6) Journal of Antimicrobial Chemotherapy. 2003;60:20–41. doi: 10.1093/jac/dkm110. [DOI] [PubMed] [Google Scholar]
  • 15.Baker J. T, Borris R. P, Carte B, Cordell G. A, Soejarto D. D, Cragg G. M, Gupta M. P, Iwu M. M, Madulid D. R, Tyler V. E. Natural productdrug discovery and development. Journal of Natural Products. 1995;58:1325–1357. doi: 10.1021/np50123a003. [DOI] [PubMed] [Google Scholar]
  • 16.Bala N, Aitken E. A. B, Fechner N, Cusack A, Steadman K. J. Evaluation of antibacterial activity of Australian basidiomycetous macrofungi using a high-throughput 96-well plate assay. Pharmaceutical Biology. 2011;49(5):492–500. doi: 10.3109/13880209.2010.526616. [DOI] [PubMed] [Google Scholar]
  • 17.Bobek P, Ozdyn L, Kuniak L. The effect of oyster (Pleurotus ostreatus) its ethanolic extracts and extraction residues on cholesterol levels in serum lipoproteins and liver of rat. Nahrung. 1995;39:98–99. doi: 10.1002/food.19950390113. [DOI] [PubMed] [Google Scholar]
  • 18.Bobek P, Galbavy S. Hypocholesterolemic and anti-atherogenic effect of oyster mushroom (Pleurotus ostreatus) in rabbit. Nahrung. 1999;43:339–342. doi: 10.1002/(SICI)1521-3803(19991001)43:5<339::AID-FOOD339>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  • 19.Bonatti M, Karnopp P, Soares H. M, Furlan S. A. Evaluation of Pleurotos ostreatus and Pleurotos sajor-caju nutritional characteristics when cultivated in different lignocelluloses wastes. Food Chemistry. 2004;88:425–428. [Google Scholar]
  • 20.Breitenbach J, Kränzlin F. F. Fungi of Switzerland. Nongilled Fungi. Verlag Mykologia CH-6000 Luzern d9, Switzerland 1986;2 [Google Scholar]
  • 21.Breitenbach J, Kränzlin F. Vol. 1. Verlag Mykologia CH-6000 Luzern9; Switzerland: 1984. Fungi of Switzerland. [Google Scholar]
  • 22.Canli K, Altuner E. M, Akata I. Antimicrobial screening of Mnium stellare Bangladesh. Journal of Pharmacology. 2015;10(2):321–325. [Google Scholar]
  • 23.Canli K, Cetin B, Altuner E. M, Turkmen Y, Uzek U, Dursun H. In vitro antimicrobial screening of Hedwigia ciliate var. leucophaea and determination of the ethanol extract composition by Gas Chromatography/Mass Spectrometry (GC/MS) Journal of Pure and Applied Microbiology. 2014;8(4):2987–2998. [Google Scholar]
  • 24.Cheung L. M, Cheung P. C. K. Mushroom extracts with antioxidant activity against lipid peroxidation. Food Chemistry. 2005;89:403–409. [Google Scholar]
  • 25.Clardy J, Walsh C. Lessons from natural molecules. Nature. 2004;432:829–837. doi: 10.1038/nature03194. [DOI] [PubMed] [Google Scholar]
  • 26.Cos P, Vlietinck A. J, Vanden Berghe D, Maes L. Anti-infective potential of natural products: How to develop a stronger in vitro ‘proof-of-concept’. Journal of Ethnopharmacology. 2006;106:290–302. doi: 10.1016/j.jep.2006.04.003. [DOI] [PubMed] [Google Scholar]
  • 27.De Boer A S, Diderichsen B. On the safety of Bacillus subtilis and B. amyloliquefaciens: A review. Applied Microbiology and Biotechnology. 1991;36:1–4. doi: 10.1007/BF00164689. [DOI] [PubMed] [Google Scholar]
  • 28.Dulger B, Sen F, Gucin F. Russula delica Fr. makrofungusunun antimikrobiyal aktivitesi. TurkishJournal of Biology. 1999;23:127–133. [Google Scholar]
  • 29.Dulger B, Yayintas O. T, Gonuz A. Antimicrobial activity of some mosses from Turkey. Fitoterapia. 2005a;76:730–732. doi: 10.1016/j.fitote.2005.07.006. [DOI] [PubMed] [Google Scholar]
  • 30.Dulger B, Suerdem T. B, Yesilyurt D, Hacioglu N, Camdeviren A. Evaluation of Antimicrobial Activity of the Macrofungus Phellinus torulosus. Journal of Biological Sciences. 2005b;5:436–439. [Google Scholar]
  • 31.Erturk O, Kati H, Yayli N, Demirbag Z. Antimicrobial Properties of Silene multifida (Adams) Rohrb. Plant Extracts. Turkish Journal of Biology. 2006;30:17–21. [Google Scholar]
  • 32.Galieni P, Bigazzi C. Recurrent septicemia in an immuno-compromised patient due to probiotic strains of Bacillus subtilis. Journal of Clinical Microbiology. 1998;36:325–326. doi: 10.1128/jcm.36.1.325-326.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Gunde-Cimerman N. Medicinal value of genus Pleurotus (Fr) P. Karst. (Agaricles S. R. Basidiomycetes) International Journal of Medicinal Mushrooms. 1999;1:69–70. [Google Scholar]
  • 34.Hammer K. A, Carson C. F, Riley T. V. Antimicrobial activity of essential oils and other plant extracts. Journal of Applied Microbiology. 1999;86:985–990. doi: 10.1046/j.1365-2672.1999.00780.x. [DOI] [PubMed] [Google Scholar]
  • 35.Hansen L, Knudsen H. Nordic Macromycetes. (Ascomycetes). Nordsvamp, Copenhagen, Denmark 2000;1 [Google Scholar]
  • 36.Imtiaj A, Lee T. S. Screening of antibacterial and antifungal activities from Korean wild mushrooms. World Journal of Agricultural Sciences. 2007;3:316–321. [Google Scholar]
  • 37.Jones F. A. Herbs - useful plants. Their role in history and today. European Journal of Gastroenterology and Hepatology. 1996;8:1227–1231. doi: 10.1097/00042737-199612000-00018. [DOI] [PubMed] [Google Scholar]
  • 38.Kauffman C. A. Fungalinfections. Proc AmThorac Soc. 2006;3:35–40. [Google Scholar]
  • 39.Khalid A, Waseem A, Saadullah M, Rehman U. U, Khiljee S, Sethi A, Asad M. H. H. B, Waqas M. K, Murtaza G. Antibacterial activityanalysis of extracts of various plants against Gram-positive and -negative bacteria. African Journal of Pharmacy and Pharmacology. 2011;5:887–93. [Google Scholar]
  • 40.Kontoyiannis D, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. Journal of Hospital Infection. 2003;53:243–258. doi: 10.1053/jhin.2002.1278. [DOI] [PubMed] [Google Scholar]
  • 41.Mahasneh A. M, El-Oqlah A. A. Antimicrobial activity of extracts of herbal plants used in the traditional medicine of Jordan. Journal of Ethnopharmacology. 1999;64:271–276. doi: 10.1016/s0378-8741(98)00132-9. [DOI] [PubMed] [Google Scholar]
  • 42.McClelland M, Sanderson K. E, Spieth J, Clifton S. W, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson R.K. Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001;413:852–856. doi: 10.1038/35101614. [DOI] [PubMed] [Google Scholar]
  • 43.Nikaido H. Antibiotic resistance caused by Gram-negative multidrug efflux pumps. Clinical Infectious Diseases. 1998;27:32–41. doi: 10.1086/514920. [DOI] [PubMed] [Google Scholar]
  • 44.Okeke I. N, Laxmaninarayan R, Bhutta Z. A, Duse A. G, Jenkins P, O’Brien T. F, Pablos-Mendez A, Klugman K. P. Antimicrobial resistance in developing countries. Part 1: recenttrends and currentstatus. Lancet Infectious Diseases. 2005;5:481–493. doi: 10.1016/S1473-3099(05)70189-4. [DOI] [PubMed] [Google Scholar]
  • 45.Onbasili D, Altuner E. M, Celik G. Y. Mniummarginatum ÖzütlerininAntimikrobiyal Aktivitesi. Kastamonu University, Journal of Forestry. 2011;11(2):205–208. [Google Scholar]
  • 46.Onbasili D, Yuvali Celik G, Altuner E. M, Altınsoy B, Aslim B. In vitro antimicrobial, antioxidant, and antibiofilm activities of Bryum capillare a bryophyte sample. Current Opinion in Biotechnology. 2013;24(Supplemet 1):113. [Google Scholar]
  • 47.Ooi V. E. C. Medicinally important fungi. In: Van Griensven., editor. Science and Cultivation of Edible Fungi. Balkerna, Rotterdam: 2000. [Google Scholar]
  • 48.Ozkan O. E, Zengin G, Akca M, Baloglu M. C, Olgun C, Altuner E. M, Ates S, Aktumsek A, Vurdu H. DNAprotection, antioxidant, antibacterial and enzyme inhibition activities of heartwood and sapwood extracts from juniper and olive woods. RSC Advances. 2015;5:72950–72958. [Google Scholar]
  • 49.Paudel B, Bhattarai H. D, Lee J. S, Hong S. G, Shin H. W, Yim J. H. Antibacterial Potential of Antarctic Lichens against Human Pathogenic Gram-positive Bacteria. Phytotheraphy Research. 2008;22:1269–1271. doi: 10.1002/ptr.2445. [DOI] [PubMed] [Google Scholar]
  • 50.Quereshi S, Pandey A. K, Sandhu S. S. EvaluationofantibacterialactivityofdifferentGanoderma lucidumextracts. People’s Journal of Scientific Research. 2010;3:9–13. 2010. [Google Scholar]
  • 51.Rojas R, Bustamante B, Bauer J, Fernandez I, Alban J, Lock O. Antimicrobial activityofselected Peruvian medicinal plants. Journal of Ethnopharmacology. 2003;88:199–204. doi: 10.1016/s0378-8741(03)00212-5. [DOI] [PubMed] [Google Scholar]
  • 52.Silici S, Koc A. N. Comparative study of in vitro methods to analyse the antifungal activity of propolis againstyeasts isolated from patients with superficial mycoses. Letters in Applied Microbiology. 2006;43:318–324. doi: 10.1111/j.1472-765X.2006.01949.x. [DOI] [PubMed] [Google Scholar]
  • 53.Syed G. W, Syed A. S, Oh L. A. RiskEvaluationUnderVarious Speculations of Antibiotic Usage;ACohortSurveyAmong Outpatients of Pinang, Malaysia. European Journal of General Medicine. 2010;7:303–309. [Google Scholar]
  • 54.Vaara M. Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother. 1993;37:2255–2260. doi: 10.1128/aac.37.11.2255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Villegas M. V, Quinn J. P. An update on antibiotic-resistant gram-negative bacteria. Infections in Medicine. 2004;21:595–599. [Google Scholar]
  • 56.Wasser S. P, Weis A. L. Medicinal properties of substances occurring in higher basidiomycete mushrooms: Current perspective. International Journal of Medicinal Mushrooms. 1999a;1:31–62. [Google Scholar]
  • 57.Wasser S. P, Weis A. L. Therapeutic properties of substances occurring in higher basidiomycete mushrooms: A modern perspective. Critical Reviews of in Immunology. 1999b;19:65–96. [PubMed] [Google Scholar]
  • 58.Webster D, Taschereau P, Belland R. J, Sand C, Rennie R. P. Antifungal activity of medicinal plant extracts;preliminaryscreening studies. Journal of Ethnopharmacology. 2008;115:140–146. doi: 10.1016/j.jep.2007.09.014. [DOI] [PubMed] [Google Scholar]

Articles from African Journal of Traditional, Complementary, and Alternative Medicines are provided here courtesy of African Traditional Herbal Medicine Supporters Initiative

RESOURCES